Immunologic Research

, Volume 54, Issue 1–3, pp 247–253 | Cite as

Complement regulation of T cell immunity

  • Wing-hong Kwan
  • William van der Touw
  • Peter S. Heeger
Immunology at Mount Sinai

Abstract

Results of studies published since 2002 reveal that T cells and antigen-presenting cells (APCs) produce complement proteins. The immune cell–derived, alternative pathway complement components activate spontaneously, yielding local, but not systemic, production of C3a and C5a. These anaphylatoxins bind to their respective G-protein-coupled receptors, C3aR and C5aR, expressed on both partners. The resultant complement-induced T cell activation and APC activation drive T cell differentiation, expansion and survival. Complement deficiency or blockade attenuates T cell-mediated autoimmunity and delays allograft rejection in mice. Increasing complement activation, achieved by genetic removal of the complement regulatory protein decay-accelerating factor, enhances murine T cell immunity and accelerates allograft rejection. The findings support the need for design and testing of complement inhibitors in humans.

Keywords

T cells Allograft rejection Complement Costimulation Autoimmunity 

Notes

Acknowledgments

This work was supported by NIH grants AI43578 and AI071185 to PSH. WK is a recipient of a fellowship grant from the American Society of Transplantation.

References

  1. 1.
    Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Baldwin WM, Ota H, Rodriguez ER. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol. 2003;25:181–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM III. Antibody and complement in transplant vasculopathy. Circ Res. 2007;100:191–203.PubMedCrossRefGoogle Scholar
  4. 4.
    Qian Z, Wasowska BA, Behrens E, Cangello DL, Brody JR, Kadkol SS, et al. C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol. 1999;155:1293–302.PubMedCrossRefGoogle Scholar
  5. 5.
    Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10:2208–14.PubMedGoogle Scholar
  6. 6.
    Stegall M, Tayyab D, Lynn C, Justin B, Patrick D, Gloor JM. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients. Am J Transplant. 2010;10(s4):39.Google Scholar
  7. 7.
    Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8:582–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Sheerin NS, Risley P, Abe K, Tang Z, Wong W, Lin T, et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J. 2008;22:1065–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol. 2009;20:593–603.PubMedCrossRefGoogle Scholar
  10. 10.
    Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160:1558–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Pepys MB. Role of complement in the induction of immunological responses. Transpl Rev. 1976;32:93–120.Google Scholar
  12. 12.
    Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med. 2005;201:1523–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28:425–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008;112:1759–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol. 2007;179:5793–802.PubMedGoogle Scholar
  17. 17.
    Li K, Anderson KJ, Peng Q, Noble A, Lu B, Kelly AP, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood. 2008;112:5084–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Peng Q, Li K, Wang N, Li Q, Asgari E, Lu B, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol. 2009;183:6058–68.PubMedCrossRefGoogle Scholar
  19. 19.
    Pavlov V, Raedler H, Yuan S, Leisman S, Kwan WH, Lalli PN, et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol. 2008;181:4580–9.PubMedGoogle Scholar
  20. 20.
    Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol. 2003;170:788–94.PubMedGoogle Scholar
  21. 21.
    Fang C, Miwa T, Shen H, Song WC. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J Immunol. 2007;179:3178–86.PubMedGoogle Scholar
  22. 22.
    Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008;180:5882–9.PubMedGoogle Scholar
  23. 23.
    Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med. 2005;201:567–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Bao L, Haas M, Pippin J, Wang Y, Miwa T, Chang A, et al. Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest. 2009;119:1264–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med. 2010;207:1135–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Lin M, Yin N, Murphy B, Medof ME, Segerer S, Heeger PS, et al. Immune cell derived C3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes. 2010;59:2247–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Esposito A, Suedekum B, Liu J, An F, Lass J, Strainic MG, et al. Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant. 2010;10:527–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Krieger NR, Yin DP, Fathman CG. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med. 1996;184:2013–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature. 1998;393:480–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Vieyra M, Leisman S, Raedler H, Kwan WH, Yang M, Strainic MG, et al. Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection. Am J Pathol. 2011;179:766–74.PubMedCrossRefGoogle Scholar
  32. 32.
    Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant. 2009;9:1784–95.PubMedCrossRefGoogle Scholar
  33. 33.
    Gueler F, Rong S, Gwinner W, Mengel M, Brocker V, Schon S, et al. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol. 2008;19:2302–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Raedler H, Vieyra MB, Leisman S, Lakhani P, Kwan W, Yang M, et al. Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant. 2011;11:1397–406.PubMedCrossRefGoogle Scholar
  35. 35.
    Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS. Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation. 2008;86:1319–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol. 2009;20:1839–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Li K, Fazekasova H, Gomes C, Wang N, Sagoo P, Peng Q, et al. Expression of complement components, receptors and regulators by human dendritic cells and the role of C3a and C5a in modulation of dendritic cell function. Mol Immunol. 2010;47:2232.CrossRefGoogle Scholar
  38. 38.
    Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med. 2006;354:2014–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Varagunam M, Yaqoob MM, Dohler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med. 2009;360:874–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Wing-hong Kwan
    • 1
  • William van der Touw
    • 1
  • Peter S. Heeger
    • 1
  1. 1.Department of Medicine, Recanati Miller Transplant Institute and Immunology InstituteMount Sinai School of MedicineNew YorkUSA

Personalised recommendations